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Abstract: Cancer immunotherapy has produced impressive clinical results in recent years. Despite
the success of the checkpoint blockade strategies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4)
and programmed death receptor 1 (PD-1), a large portion of cancer patients have not yet benefited
from this novel therapy. T cell immunoglobulin and mucin domain 3 (TIM-3) has been shown to
mediate immune tolerance in mouse models of infectious diseases, alloimmunity, autoimmunity, and
tumor Immunity. Thus, targeting TIM-3 emerges as a promising approach for further improvement
of current immunotherapy. Despite a large amount of experimental data showing an immune
suppressive function of TIM-3 in vivo, the exact mechanisms are not well understood. To enable
effective targeting of TIM-3 for tumor immunotherapy, further in-depth mechanistic studies are
warranted. These studies will also provide much-needed insight for the rational design of novel
combination therapy with other checkpoint blockers. In this review, we summarize key evidence
supporting an immune regulatory role of TIM-3 and discuss possible mechanisms of action.
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1. Introduction
Immune checkpoint inhibitors targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed
death receptor 1 (PD-1) have been proven highly effective in fighting cancer. Ipilimumab—a fully
humanized cytotoxic T-lymphocyte–associate-d antigen 4 (CTLA-4) antibody—was the first immune
checkpoint inhibitor associated with an improvement in overall survival in a phase 3 study involving
patients with metastatic melanoma [1,2]. Approximately 20% of patients treated with Ipilumumab
had long-term survival [3,4]. Evidence suggests at least part of the mechanism of action of CTLA-4
monoclonal antibody (mAbs) functions by depleting regulartory T cells (Tregs) [5,6]. PD-1 is a key
checkpoint molecule expressed in exhausted CD8+ T cells and Tregs. Blockade of PD-1 has achieved
revolutionary clinical impact in many solid cancers [7–18]. Despite these encouraging results, large
portions of cancer patients fail to respond to these therapies. One likely roadblock is the compensatory
immune inhibitory pathways. Therefore, there is an urgent need to further improve these therapies by
simultaneously targeting multiple immune checkpoint pathways.
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T cell immunoglobulin and mucin domain 3 (TIM-3) has been recognized as a member of the
TIM gene family, which includes TIM-1, TIM-3, TIM-4 in humans and Tim-1-8 in mice. TIM-3 is
expressed on Th1, Th17, CD8+ T cells–cells of myeloid lineages [19–21] in mice. Engagement between
TIM-3 and its ligands has been found to suppress Th1 and Th17 responses [22] and induce peripheral
immune tolerance [23,24], supporting an inhibitory role of TIM-3 in T cell-mediated immune responses.
TIM-3 expression also characterizes exhausted T cells during chronic infection [25–28]. In this setting,
TIM-3-expressing CD4+ and CD8+ T cells produce reduced amounts of cytokine or are less proliferative
in response to antigen [25–28]. Experiments with TIM-3 mAbs suggest that it plays a functional
role in exhausted T cells. TIM-3 mAbs restores proliferation and enhances cytokine production in
HIV-1-specific T cells in vitro [25]. Administration of TIM-3 and PD-1 mAbs synergistically control
tumor growth [29–32]. These preclinical studies implicate an inhibitory role of TIM-3 in antitumor
Immunity. However, the underlying mechanisms are not well understood and seemingly even
contradictory to its well established T cell-stimulating function [33].
Herein, we summarize key evidence indicating an immune regulatory role of TIM-3. We further
discuss possible mechanisms of action by which TIM-3 regulates immune responses in infectious
immunity, autoimmunity, and tumor Immunity. We will discuss feasible approaches for targeting
TIM-3 for cancer immunotherapy.
2. Molecular Characteristics of TIM-3, Its Ligands, and Signal Transduction
The TIM family is comprised of type I membrane proteins, which share a similar structure: a variable
immunoglobulin domain (IgV), a glycosylated mucin domain of varying length in the extracellular
region, and a single transmembrane domain [34–39]. With the exception of Tim-4, all TIM molecules
also contain a C-terminal cytoplasmic tail with a conserved tyrosine-based signal motif [34–39]. There
are six cysteines within the IgV domain of TIM-3, which makes this IgV domain different from others.
Most TIM IgV regions contain four cysteines, which form two disulfide bridges that contribute to the
formation of a unique binding surface [34]. In the classical IgV model, FG and CC’ loops are located at
opposite ends of the domain, with a distance of 25 Å. However, in the TIM-3 protein, the CC’ loop is
reoriented closer to the FG loop due to an additional disulfide bond [34,40]. Under this circumstance,
a unique binding pocket (FG-CC′ cleft) is created, which is required for interactions with ligands of
TIM-3 (Figure 1).
So far, four relevant ligands have been shown to interact with the IgV domain of TIM-3
(Figure 1) [41]. These include galectin-9 (Gal-9), high mobility group protein B1 (HMGB1),
carcinoembryonic antigen cell adhesion molecule 1 (Ceacam-1), and phosphatidylserine (PtdSer).
Gal-9, the first identified ligand, can bind to the carbohydrate motif on TIM-3 and incite an influx of
calcium to the intracellular region of Th1 cells, inducing apoptosis [22]. It is important to note that
glycosylation of the IgV is required for Gal-9 binding [22]. PtdSer, a molecule exposed on the surfaces
of apoptotic cells, is another TIM-3 ligand. PtdSer was shown to bind to a pocket within the IgV
domain of TIM-1, TIM-3, and TIM-4 [42]. This interaction facilitates the clearance of apoptotic bodies
and also promotes the cross-presentation of antigens by dendritic cells (DCs) [43]. The third TIM-3
ligand identified is high mobility group protein B1 (HMGB1). TIM-3 is highly expressed on tumor
infiltrating DCs and actively competes with nucleic acids released from dying tumor cells to bind
HMGB1, effectively inhibiting stimulation of the innate immune response by nucleic acids [44]. As a
result, activation of innate immunity and production of pro-inflammatory cytokines can be attenuated.
Carcinoembryonic antigen cell adhesion molecule 1 (Ceacam-1) expressed on the cell surface is a more
recently identified ligand for TIM-3. Ceacam-1 and TIM-3 are co-expressed, and the two molecules can
form in trans a specific heterodimer which functions as a negative regulator of T cell responses [45].
The interaction between Ceacam-1 and TIM-3 can be either cis or trans, and both types of interactions
can mediate T cell immune tolerance.
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Figure 1. T cell immunoglobulin and mucin domain 3 (TIM-3), its ligands, and signaling adaptor 
proteins. Four ligands—namely, galectin-9 (Gal-9), phosphatidylserine (PtdSer), high mobility group 
protein B1 (HMGB1), and carcinoembryonic antigen cell adhesion molecule 1 (Ceacam-1)—have 
been identified to bind to the variable immunoglobulin (IgV) domain of TIM-3. In terms of signaling, 
HLA-B associated transcript 3 (Bat-3) binds to the cytoplasmic tail of TIM-3 and inhibits TIM-3 
function. Fyn, Lck, and Itk, three tyrosine kinases, bind and phosphorylate specific tyrosine residues 
within the cytoplasmic domain of TIM-3. The phosphorylated tyrosines within the cytoplasmic 
domain of TIM-3 can recruit other downstream signaling adaptors such as p85 adaptor protein. In 
addition, Gal-9 can mediate the formation of clusters containing TIM-3, CD45, and CD148. 
TIM-3 is involved in the proximal signaling events in T cells. However, there is evidence 
supporting both positive and negative effects of TIM-3 on TCR (T cell receoptor) signaling. Transient 
expression of TIM-3 increases TCR signaling to NFAT and NF-κB in Jurkat T cells and 
phosphorylation of tyrosines 256 and 263 is required, but the ecto domain of TIM-3 is not required 
for this function of TIM-3 [36]. Several members of the Src kinase family—such as Lck, Fyn and 
Itk—have been shown to bind and phosphorylate TIM-3 tyrosines [36,46]. The phosphorylated 
tyrosines within the cytoplasmic domain of TIM-3 can then recruit p85 adaptor protein, leading to 
the activation of PI3 kinases. TIM-3 has also been shown to inhibit TCR proximal signaling [47,48]. In 
TIM-3+ CD8+ effector T cells, Gal-9 is shown to induce co-localization of TIM-3 with receptor 
phosphatases CD45 and CD148, and thereby inhibits TCR signaling [49]. Another report shows that 
TIM-3 is stably expressed in Jurkat cells inhibits TCR-mediated NF-κB/NFAT activation [49]. Bat-3 
has been shown to bind to the cytoplasmic tail of TIM-3, and Gal-9-triggered phosphorylation of 
tyrosines 256 and 263 leads to its release from TIM-3 [47]. Bat-3 reverses the negative effect of TIM-3 
on TCR signaling, likely by recruiting active Lck or blocking the binding of Fyn to TIM-3 [41,47]. 
Therefore, the effect of TIM-3 on TCR signaling is dependent on cellular context (positive for 
naïve/effector/memory T cells versus negative for exhausted T cells) or the ligands it engages. 
3. Tim-3 Mediates Immune Tolerance in Autoimmunity and Alloimmunity 
In earlier studies, TIM-3 was shown to be involved in the regulation of autoimmune diseases in 
both mouse models and human patients. Treatment with TIM-3 mAb enhances the severity of 
experimental autoimmune encephalomyelitis (EAE) [21]. Lower expression of TIM-3 on T cells and 
higher production of interferon (IFN)-γ can be detected in patients suffering from multiple sclerosis 
(MS) [50]. TIM-3-Ig fusion protein or anti-TIM-3 mAb can accelerate autoimmune diabetes by 
Figure 1. T cell immunoglobulin and mucin domain 3 (TIM-3), its ligands, and signaling adaptor proteins.
Four ligands—namely, galectin-9 (Gal-9), phosphatidylserine (PtdSer), high mobility group protein B1
(HMGB1), and carcinoembryonic antigen cell adhesion molecule 1 (Ceacam-1)—have been identified to
bind to the variable immunoglobulin (IgV) domain of TIM-3. In terms of signaling, HLA-B associated
transcript 3 (Bat-3) binds to the cytoplasmic tail of TIM-3 and inhibits TIM-3 function. Fyn, Lck, and
Itk, three tyrosine kinases, bind and phosphorylate specific tyrosine residues within the cytoplasmic
domain of TIM-3. The phosphorylated tyrosines within the cytoplasmic domain of TIM-3 can recruit
other downstream signaling adaptors such as p85 adaptor protein. In addition, Gal-9 can mediate the
formation of clusters containing TIM-3, CD45, and CD148.
TIM-3 is invol ed in the proximal signalin eve ts in T cells. How ver, there is videnc supporting
both sitive and nega effects of TIM-3 on TCR (T cell receoptor) signaling. Tran e t expression of
TIM-3 increases TCR signaling to NFAT and NF-κB in Jurkat T cells and phosphorylation of tyro ines
256 and 263 is required, but the ecto domain of TIM-3 is not required for this function of TIM-3 [36].
Several members of the Src kinase family—such as Lck, Fyn and Itk—h ve been shown to bind and
phosphorylate TIM-3 tyrosines [36,46]. The phosphorylated tyrosines within the cytoplasmic dom in
of TIM-3 can en recruit 85 adapt r protein, leading to the activation of PI3 kinases. TIM-3 has
also been sh wn to inh bit TCR proximal signali g [47,48]. In TIM-3+ CD8+ effector T cells, Gal-9 is
shown to induc co-localization of TIM-3 with receptor phosphatases CD45 and CD148, and ther by
inhibits TCR signaling [49]. Another report shows that TIM-3 is stably expressed in Jurkat cells inhibits
TCR-media ed NF-κB/NFAT activ ion [49]. Bat-3 has been shown to bind to the cytoplasmic t il
of TIM-3, and Gal-9-tr ggered phosphorylation of tyrosines 256 and 263 leads to its release from
TIM-3 [47]. Bat-3 revers s the negative effect of TI -3 on TCR signaling, likely by recruiting active
Lck or blocki g the b nding of Fyn to TIM-3 [41,47]. Therefore, the effect of TIM-3 on TCR signaling
is dep nd nt on cellular context (positive for naïve/effector/mem ry T cells versus negat ve for
exhaust d T cells) or the ligands it engag s.
3. Tim-3 Mediates Im une Tolerance in Autoim unity and Alloim unity
In earlier studies, TIM-3 was sho n to be involve in the reg lation of autoi mune diseases
in both mouse models and h an atients. reat ent ith I -3 Ab enhances the severity of
experimental autoim une encephalomyelitis (EAE) [21]. Lower expression of TIM-3 on T cells and
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higher production of interferon (IFN)-γ can be detected in patients suffering from multiple sclerosis
(MS) [50]. TIM-3-Ig fusion protein or anti-TIM-3 mAb can accelerate autoimmune diabetes by blocking
TIM-3-mediated immune tolerance [23]. These studies suggest that TIM-3 is an immune checkpoint
molecule. Similar observations were also made in the transplantation setting. Administration of the
TIM-3-Ig fusion protein prevented transplantation tolerance, and this function of TIM-3 is dependent
on donor-specific CD4+CD25+ regulatory T cells [24]. Many other studies further support a critical role
of TIM-3 in suppressing the rejection of transplanted skin [24], pancreatic islets [24], heart [51], and
bone marrow allografts [52]. These studies indicate that TIM-3 signaling—or at least the immune cells
expressing TIM-3—mediates immune tolerance. However, the in vivo mechanisms are still not clear.
4. TIM-3 in Immune Tolerance to Tumors
Recently, TIM-3 has been shown to be highly expressed on tumor antigen-specific T cells in
the peripheral blood and among tumor infiltrating lymphocytes (TIL), suggesting a role of TIM-3 in
tumor Immunity. Up-regulation of TIM-3 is associated with the exhaustion of tumor antigen-specific
CD8+ T cells in melanoma patients, and administration of TIM-3 mAbs can reverse tumor-induced
T cell exhaustion [29,53]. In human patients with non-small cell lung cancer (NSCLC), TIM-3 is
predominantly expressed in tumor-infiltrating CD4+ and CD8+ T cells, but expressed at minimal levels
on T cells from peripheral blood. In addition, among CD4+ TIL, TIM-3 is preferentially expressed
on Foxp3+ CD4+ Treg cells, and the frequency of CD4+TIM-3+ TIL is correlated with poor patient
survival [54]. TIM-3 was also shown to be expressed in TIL or tumor antigen-specific T cells in
peripheral blood from many cancer types such as hepatocellular cancer, cervical cancer, colorectal
cancer, ovarian cancer [55], NSCLC [56,57], head and neck cancer [58], renal cell carcinoma (RCC) [59],
gastric cancer [60], esophageal cancer [61], prostate cancer [62], and non-Hodgkin lymphoma [63].
In preclinical models, administration of TIM-3 mAbs alone has produced variable antitumor
effects. TIM-3 has been shown to be upregulated in TIL in mouse tumor models such as CT26
colon adenocarcinoma, 4T1 mammary adenocarcinoma, and B16F10 melanoma [64]. On its own,
administration of TIM-3 mAbs did not inhibit tumor growth in the CT26 model. However, combination
of TIM-3 and PD-1 mAbs had a much greater antitumor effect than administration of TIM-3 or PD-1
mAbs alone [64]. Another study showed that TIM-3 mAbs injection slowed tumor progression in many
mouse tumor models, such as MC38 colon carcinoma, WT3 sarcoma, CT26 colon adenocarcinoma,
and TRAMP-C1 prostate tumor [65]. Furthermore, combination of TIM-3 mAbs and CTLA4 mAbs,
or TIM-3 mAbs and PD-1 mAbs has had much greater antitumor effects [65]. These studies have
established that targeting TIM-3 with monoclonal antibodies is a viable new immunotherapy for cancer.
In addition, rational combinations of TIM-3 mAbs with the PD-1 mAbs and/or CTLA4 mAbs have
great potential to further improve the current immunotherapeutic approaches to cancer. Currently,
a Phase I-Ib/II open-label multi-center study of the safety and efficacy of TIM-3 mAbs as single
agent and in combination with PD-1 mAbs in adult patients with advanced malignancies is ongoing
(ClinicalTrials.gov Identifier: NCT02608268).
5. Targeting TIM-3 for Immunotherapy of Cancer
TIM-3 signaling directly regulates the function of Th1 and CD8+ T cells through various mechanisms
(Figure 2). TIM-3 is induced in Th1 cells and inhibits Th1-mediated immune responses by directly
triggering apoptosis [22]. TIM-3 has also been identified as a marker for exhausted CD8+ T cells in
patients with chronic infections such as HIV or hepatitis C virus [25,27]. In cancer patients, TIM-3 is
upregulated on tumor antigen-specific CD8+ T cells and CD8+ TIL [29,53,54,64]. Administration
of TIM-3 mAbs increases proliferation and cytokine production by tumor antigen-specific T
cells [29,53,54,64,65]. These data support the idea that the exhaustion of T cells is involved in the
establishment of an immune suppressive state in cancer.
However, one must be cautious when considering TIM-3 for the purpose of boosting CD8+ T
cell-mediated immune responses. Despite the antitumor efficacy seen with TIM-3 mAbs, TIM-3 has
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been shown to promote CD8+ T cells function in the setting of listeria infection [33]. It is possible that
although TIM-3 expression is associated with CD8+ T cell exhaustion during chronic infection and
tumor immune suppression, it may also promote the initial generation of effector CD8+ T cells during
acute infection.
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Figure 2. Summary of multiple biological functions of TIM-3 on various immune cells. TIM-3 
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exhaustion. The effect on Tregs remains unknown. Likely dependent on the cellular context, TIM-3 
signaling can enhance cross-presentation of dendritic cells (DC) or inhibit innate immune responses 
of DC and macrophages. 
TIM-3 is also found to be upregulated on CD4+ T cells in patients with chronic infection and 
cancer [25,27,54,64]. It is possible that TIM-3 is an exhaustion marker for Th1 cells [25,27]. It is 
important to note that a substantial proportion of CD4+TIM-3+ TIL are Foxp3+, suggesting a role for 
TIM-3 in Treg within the tumor microenvironment (TME) [64]. Besides tumor tissues, TIM-3 has also 
been found in many tissue-resident Tregs [66], and plays an important role in both maintaining 
immune tolerance as well as tissue repair [67–70]. It remains to be determined whether or not TIM-3 
mAbs function in tumor immunotherapy—at least in part—by inhibiting the function of 
tumor-infiltrating Treg (Figure 2). 
Ample evidence supports a role for TIM-3 as an inhibitory receptor on NK cells. TIM-3 is highly 
expressed on mature human NK cells and is variably expressed on immature NK cells [71]. TIM-3 
marks NK cells with greater effector function, including cytokine production and cytotoxicity. 
However, cross-linking of TIM-3 inhibits NK cell-mediated cytotoxicity, suggesting that interaction 
of TIM-3 with one or more of its ligands negatively regulates NK cell activity [71]. In another study, 
TIM-3 expression was increased on NK cells from patients infected chronically with hepatitis B [72]. 
TIM-3 blockade ex vivo increased cytotoxicity of NK cells from these patients, suggesting that TIM-3 
inhibits NK function in chronic infection. Many other studies further support an inhibitory role of 
TIM-3 in NK cell-mediated immune responses [73,74–76]. In contrast, some studies demonstrated a 
positive role of TIM-3 in NK function [77]. Therefore, TIM-3 might play both stimulatory and 
inhibitory roles in NK cells, depending on cellular and pathological context. The role of TIM-3 on 
NK cells in the tumor microenvironment remains to be examined (Figure 2). 
Figure 2. Summary of multiple biological functions of TIM-3 on various immune cells. TIM-3 signaling
in T cells and NK cells leads to the development of effector functions, apoptosis, or exhaustion.
The effect on Tregs remains unknown. Likely dependent on the cellular context, TIM-3 signaling
can enhance cross-presentation of dendritic cells (DC) or inhibit innate immune responses of DC
and macrophages.
TIM-3 is also found to be upregulated on CD4+ T cells in patients with chronic infection and
cancer [25,27,54,64]. It is possible that TIM-3 is an exhaustion marker for Th1 cells [25,27]. It is
important to note that a substantial proportion of CD4+TIM-3+ TIL are Foxp3+, suggesting a role for
TIM-3 in Treg within the tumor microenvironment (TME) [64]. Besides tumor tissues, TIM-3 has also
been found in many tissue-resident Tregs [66], and plays an important role in both maintaining immune
tolerance as well as tissue repair [67–70]. It remains to be determined whether or not TIM-3 mAbs
function in tumor immunotherapy—at least in part—by inhibiting the function of tumor-infiltrating
Treg (Figure 2).
Ample evidence supports a role for TIM-3 as an inhibitory receptor on NK cells. TIM-3 is highly
expressed on mature human NK cells and is variably expressed on immature NK cells [71]. TIM-3
marks NK cells with greater effector function, including cytokine production and cytotoxicity. However,
cross-linking of TIM-3 inhibits NK cell-mediated cytotoxicity, suggesting that interaction of TIM-3
with one or more of its ligands negatively regulates NK cell activity [71]. In another study, TIM-3
expression was increased on NK cells from patients infected chronically with hepatitis B [72]. TIM-3
blockade ex vivo increased cytotoxicity of NK cells from these patients, suggesting that TIM-3 inhibits
NK function in chronic infection. Many other studies further support an inhibitory role of TIM-3 in
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NK cell-mediated immune responses [73–76]. In contrast, some studies demonstrated a positive role
of TIM-3 in NK function [77]. Therefore, TIM-3 might play both stimulatory and inhibitory roles in
NK cells, depending on cellular and pathological context. The role of TIM-3 on NK cells in the tumor
microenvironment remains to be examined (Figure 2).
Besides lymphocytes, TIM-3 has been shown to be expressed by various myeloid cells (e.g., DCs,
monocytes, and macrophages), and to play an important role in regulating innate immune
cell-mediated anti-viral infection and antitumor immune responses (Figure 2) [78]. TIM-3 is expressed
on splenic CD8+ DCs [19,43]. Both Gal-9 and an agonistic TIM-3 mAb were reported to promote DC
maturation and increase proinflammatory cytokine production [19,79]. TIM-3 mediates the uptake of
apoptotic cells and the cross-presentation of antigen by DCs via TIM-3 binding to PtdSer [43]. TIM-3
mAbs inhibit this function of TIM-3 and inhibit cross-presentation of tumor antigens [43]. Despite
evidence of a positive role for TIM-3 in DC function, other studies suggest that TIM-3 mediates
inhibitory signals in DC, particularly in the TME. TIM-3 mAbs inhibited the activation and maturation
of bone marrow-derived DCs by blocking the NF-κB pathway [80]. In tumor tissues, HMGB1—a ligand
of TIM-3—is believed to act together with tumor-derived nucleic acids to gain access to endosomal
vesicles and activate innate immune responses by DCs [81]. Through direct interaction with HMGB1,
TIM-3—which is highly expressed on tumoral DCs—circumvents the stimulatory effects of nucleic
acids in tumor immunity [81]. It is possible that the exact role of TIM-3 is dependent on the type of DC
where it is expressed and the specific ligand through which it primarily engages these cells.
TIM-3 has been shown to be involved in both promoting and inhibiting the function of monocytes
and macrophages. It was reported that antibodies to TIM-3 led to increased activation of macrophages
and aggravated autoimmune disease [21]. In the same vein, TIM3-specific mAbs and TIM-3
overexpression in macrophages inhibited TLR4-stimulated inflammatory cytokine production and
promoted sepsis in vivo [82]. TIM-3 is constitutively expressed by primary CD14+ monocytes, and
blockade of TIM-3 signaling or silencing of TIM-3 expression led to a significant increase in interleukin
(IL)-12 and IL-10 production and a decrease in PD-1 [83,84]. These findings suggest that TIM-3 acts as
a negative regulator of macrophages and monocytes during innate immune responses. In contrast,
several studies indicated that interaction of Gal-9 and TIM-3 resulted in the activation of macrophages
and promoted antibacterial activity, though still-undefined mechanisms [85–88].
The phenotype of myeloid cells is highly influenced by tumor progression. Tumor-associated
macrophages (TAMs) and myeloid-derived suppressor cells are highly increased in the TME. TIM-3 is
expressed on TAMs in a variety of tumors, including hepatocellular carcinoma, lung cancer, clear cell
renal cell carcinoma, osteosarcoma, Langerhans cell sarcoma, and neoplasms derived from histiocytic
and dendritic cells [89–93]. Interestingly, transgenic overexpression of TIM-3 driven by the CD2
promoter on some T cells resulted in an increase in systemic levels of CD11b+Ly-6G+ granulocytic
myeloid-derived suppressor cells (MDSC) and inhibition of immune responses [94]. These data are
consistent with a role for TIM-3 in immune suppression. Mechanisms by which TIM-3 affects the
generation and function of TAMs and MDSCs remain to be elucidated.
6. Conclusions and Perspective
At present, TIM-3 is generally acknowledged as a negative regulator of antitumor Immunity.
Several properties of TIM-3 make it an ideal target for the next generation of immunotherapy.
For example, its selective expression on intratumoral T cells may allow for more precise therapy
via the targeting of tumor-infiltrating T cells, potentially reducing non-specific toxicity. In addition,
signaling downstream of TIM-3 is rather distinct from that of CTLA-4 and PD-1, which have reasonably
well-defined inhibitory mechanisms. By contrast, TIM-3 can both enhance and inhibit proximal
signaling in T cells, depending on the cellular context. Therefore, the distinctive expression and
intracellular signaling suggest a great potential for targeting TIM-3 alone and in combination with
current PD-1 and CTLA-4-based immunotherapy of cancer.
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Accumulating data support the concept that TIM-3 blockade can increase cell-mediated antitumor
immune responses. In addition, TIM-3 mAbs may synergize with other immunotherapy modalities to
increase antitumor efficacy. However, due to the expression of TIM-3 in both myeloid cells and
lymphocytes, the exact cellular mechanisms underlying the in vivo antitumor activity of TIM-3
mAbs are still not understood. This issue is particularly critical because TIM-3 has been shown
to both promote and inhibit cellular immune responses, depending on the models used. A thorough
understanding of the roles of different cell types that express TIM-3 in various tumors and tumor
immunotherapy models is crucial for further drug development targeting TIM-3 and design of
combination therapy with PD-1 or CTLA-4 mAbs.
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